Long-term hemoglobin supply strengthens development of Bioxytran's investigational Universal Oxygen Carrier platform
BOSTON, June 18, 2025 — Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing investigational carbohydrate-based therapeutics and oxygen transport technologies for significant unmet medical needs, today announced that it has secured a GMP-quality source of camel hemoglobin to support the continued development of its investigational Universal Oxygen Carrier (UOC) program.
The supply relationship was established with support from the Heme Foundation, a nonprofit organization focused on developing alternatives to conventional blood transfusion systems. Bioxytran and the Heme Foundation are collaborating through a $10 million joint venture focused on the development of a Universal Oxygen Carrier designed to transport oxygen without relying on conventional donor blood.
Securing a consistent source of GMP-quality hemoglobin represents an important development milestone for the UOC program, providing Bioxytran with access to a key biological component needed for continued research, development, and potential future manufacturing activities.
The UOC program is intended to investigate an alternative approach to oxygen delivery that could address limitations associated with conventional blood transfusion logistics.
Unlike donated blood, an oxygen carrier is being developed with the objective of providing oxygen transport without requiring the same donor-dependent supply chain and cold-storage infrastructure associated with conventional red blood cell transfusions.
Bioxytran serves as the Heme Foundation's primary contractor for the UOC development program. Under the terms of the joint venture, Bioxytran retains full intellectual property rights related to UOC development.
The program is being evaluated as part of the Company's broader oxygen-transport research platform.
Hemoglobin is the protein within red blood cells responsible for binding and transporting oxygen throughout the body. For an artificial or universal oxygen carrier, the characteristics of the hemoglobin source are therefore an important consideration in developing a stable oxygen transport system.
Bioxytran selected camel hemoglobin for investigation based on several properties that may be relevant to oxygen-carrier development.
Camel hemoglobin has evolved in an animal adapted to environments characterized by high temperatures, dehydration, and variable salt concentrations. These physiological adaptations have been associated with structural and functional characteristics that may contribute to hemoglobin stability under challenging conditions.
Research has also examined differences in the behavior of camel hemoglobin compared with hemoglobin from other animal sources, including characteristics associated with oxygen binding and protein stability.
These properties provide a scientific rationale for evaluating camel hemoglobin as a component of the UOC platform. Further development work will be required to determine how these characteristics translate into the performance, stability, safety, and scalability of a finished oxygen-carrier product.
A reliable supply of appropriately manufactured hemoglobin is an important requirement for advancing an oxygen-transport technology from laboratory research toward further development.
The newly secured source is intended to provide GMP-quality camel hemoglobin, supporting Bioxytran's ability to continue characterization and development activities associated with the UOC platform.
Establishing a longer-term supply relationship may also help the Company evaluate manufacturing requirements and develop a more consistent supply chain as research progresses.
For an investigational oxygen carrier, manufacturing consistency is particularly important because the properties of the hemoglobin component can influence oxygen-binding behavior, stability, formulation, and ultimately the performance characteristics of the final product.
The UOC program also supports Bioxytran's broader research into oxygen transport technologies, including its investigational oxygen therapeutic BXT-25.
BXT-25 is being developed as an oxygen transport molecule designed to investigate whether improved oxygen delivery can benefit tissues affected by reduced oxygen availability.
The Company is evaluating oxygen-transport approaches across potential applications involving stroke, traumatic brain injury (TBI), dementia, and Alzheimer's disease, among other conditions associated with tissue injury or impaired oxygen delivery.
While the UOC and BXT-25 programs represent distinct development programs, research generated through the UOC platform could contribute to Bioxytran's broader understanding of oxygen transport, formulation, and delivery.
Conventional blood transfusion depends on a complex infrastructure involving blood donation, collection, testing, processing, storage, transportation, and distribution.
The Heme Foundation was established with the goal of developing alternatives to conventional blood transfusion systems that could reduce dependence on donor blood and address logistical challenges associated with blood availability and storage.
An effective Universal Oxygen Carrier could potentially provide a more flexible approach to oxygen delivery in situations where compatible blood is unavailable or conventional transfusion infrastructure is difficult to access.
However, the UOC remains an investigational technology, and substantial research and development will be necessary to establish its safety, efficacy, manufacturing characteristics, and potential clinical applications.
Bioxytran's work in oxygen transport is based on the premise that improving oxygen availability at the tissue level may have therapeutic relevance across multiple conditions.
The Company is investigating technologies designed to address aspects of oxygen delivery and tissue hypoxia, complementing its research in carbohydrate-based therapeutics and glycobiology.
The UOC program expands this research into the development of an oxygen-carrying system based on hemoglobin, while BXT-25 represents a separate investigational approach to oxygen transport.
Together, these programs provide Bioxytran with multiple avenues for investigating how oxygen delivery can be improved in conditions where inadequate tissue oxygenation may contribute to disease or injury.
With a GMP-quality camel hemoglobin source now secured, Bioxytran will continue development activities associated with the UOC program, including further characterization, formulation, manufacturing, and evaluation of the technology.
The Company will also continue working with the Heme Foundation to advance the program and assess opportunities for additional research and development funding.
Additional preclinical and clinical research will be required before the UOC can be evaluated for potential use in humans.
“Securing a reliable GMP-quality source of camel hemoglobin represents an important milestone for the continued development of the Universal Oxygen Carrier program,” said David Platt, CEO of Bioxytran, Inc. “This relationship strengthens our collaboration with the Heme Foundation and provides an important foundation for advancing our research into oxygen transport technologies. We look forward to continuing development of the UOC while building on the broader oxygen-transport research supporting BXT-25.”
The Heme Foundation is a 501(c)(3) nonprofit organization founded in 2021 and based in Bethlehem, Pennsylvania. The organization is focused on developing alternatives to conventional blood transfusion systems through Universal Oxygen Carrier technology, with the goal of addressing challenges associated with blood supply, distribution, and cold-chain storage.
Bioxytran, Inc. is a clinical-stage biotechnology company developing investigational technologies designed to address significant unmet medical needs.
The Company's research programs include glycovirology, carbohydrate drug design, galectin biology, and oxygen transport. Bioxytran's lead investigational antiviral candidate, ProLectin-M, is an orally administered galectin antagonist being studied for viral diseases. The Company is also advancing investigational oxygen-transport technologies, including BXT-25 and its Universal Oxygen Carrier program.
Bioxytran's research is focused on developing novel therapeutic approaches for conditions involving viral infection, tissue hypoxia, inflammation, fibrosis, and tissue injury.
This news release contains forward-looking statements within the meaning of applicable securities laws, including statements concerning the development of Bioxytran's Universal Oxygen Carrier program, the potential applications and performance of camel hemoglobin, manufacturing activities, future research, funding opportunities, BXT-25, potential therapeutic applications, clinical development, and regulatory pathways.
These statements are based on current expectations and are subject to risks, assumptions, and uncertainties that could cause actual results to differ materially from those expressed or implied. Factors that may affect future results include preclinical and clinical research outcomes, manufacturing requirements, regulatory decisions, funding availability, development timelines, intellectual property considerations, strategic partnerships, and other risks described in Bioxytran's filings with the U.S. Securities and Exchange Commission.
The UOC and BXT-25 are investigational technologies and have not been approved by the U.S. Food and Drug Administration for any indication. Additional research is required to establish their safety and efficacy.
Bioxytran undertakes no obligation to update forward-looking statements except as required by applicable law.
Bioxytran, Inc.
Website: www.bioxytraninc.com
Investor Contact:
David Platt, PhD
Chief Executive Officer
Bioxytran, Inc.
617-484-1199
info@bioxytraninc.com
